EXACT Sciences Corporation

EXACT Sciences — Investor Day (June 2023)

127 slides from EXACT Sciences's investor day presentation, Jun 21, 2023

  1. Slide 1: We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment

    We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment. June 21, 2023 EXACT SCIENCES

  2. Slide 2: Safe harbor and non-GAAP disclosures

    Safe harbor and non-GAAP disclosures This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are sub

  3. Slide 3: Today's agenda

    Today’s agenda 10:00 am Welcome and opening Kevin 10:20 am Invest in world-class talent Sarah 10:25 am Tests that impact decisions Jorge, Jake, Brian Kevin Conroy Sarah Condella CHAIRMAN AND CEO EVP, HUMAN RESOURCES 11:10 am Generate rock-solid evidence Jorge 11:25 am Increase access & drive adoptio

  4. Slide 4: EXACT SCIENCES

    EXACT SCIENCES 4 EXACT SCIENCES 4

  5. Slide 5: We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment

    We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment. Kevin Conroy Chairman and CEO EXACT SCIENCES 5

  6. Slide 6: Our core values are embedded in everything we do

    Our core values are embedded in everything we do MAY 2023-MAY 2024 USA Innovation Quality Teamwork Integrity Accountability EXACT SCIENCES 6

  7. Slide 7: Leadership expectations and behaviors

    LEADERSHIP Seeks and acts One team Takes personal Acts like an EXPECTATIONS on feedback approach – puts accountability to owner – makes team ahead of deliver quality decisions and self results moves AND quickly BEHAVIORS HUMILITY WILL Celebrates Relentlessly success and Acts on Listens, thinks, focu

  8. Slide 8: Invest in world-class talent dedicated to fighting cancer

    Invest in world-class talent dedicated to fighting cancer Drive profitable Offer tests that revenue impact decision-making Provide a seamless Generate experience for rock-solid clinical customers evidence Increase access & drive adoption EXACT SCIENCES 8

  9. Slide 9: Progress towards eradicating cancer

    Progress towards eradicating cancer TOP-LINE VISIONARY BLUE-C RESULTS COLLABORATIONS EXACT SCIENCES 9

  10. Slide 10: A new standard in next-generation non-invasive screening

    A new standard in next-generation non-invasive screening EXACT SCIENCES 10

  11. Slide 11: DeeP-C vs BLUE-C performance

    87% 91% specificity including non- specificity including non- advanced findings advanced findings 90% 93% specificity including specificity including no findings no findings 92% 94% DeeP-C BLUE-C next-generation cancer cancer sensitivity sensitivity 69% 75% high-grade dysplasia high-grade dysplasia

  12. Slide 12: How we help detect cancer earlier and provide smarter answers at every step

    How we help detect cancer earlier and provide smarter answers at every step Hereditary testing Screening & diagnosis MRD & recurrence expected 2023 multi-cancer liver, esophageal, & others Early-stage therapy Prognosis & prediction Includes tests in development, which are EXACT SCIENCES not availabl

  13. Slide 13: EXACT SCIENCES

    EXACT SCIENCES 13 13

  14. Slide 14: Invest in world-class talent

    Invest in world-class talent Sarah Condella EVP, Human Resources EXACT SCIENCES 14 14

  15. Slide 15: Invest in world-class talent dedicated to fighting cancer

    Invest in world-class talent dedicated to fighting cancer Drive profitable Offer tests that revenue impact decision-making Provide a seamless Generate experience for rock-solid clinical customers evidence Increase access & drive adoption EXACT SCIENCES 15

  16. Slide 16: EXACT SCIENCES

    EXACT SCIENCES 16

  17. Slide 17: The driving force behind our flywheel is our team

    The driving force behind our flywheel is our team 6,300+ teammates dedicated to defeating cancer 54% 40+ locations globally in 18 cities gender diversity 100% of teammates are shareholders Source: Exact Sciences internal data EXACT SCIENCES 17

  18. Slide 18: Attract, develop, retain

    ATTRACT DEVELOP RETAIN EXACT SCIENCES 18 18

  19. Slide 19: Our magnetic, purpose-driven culture attracts the best talent

    ATTRACT Our magnetic, purpose-driven culture attracts the best talent 23K+ 2017 2018 2019 2020 2021 2022 1Q23 AVERAGE # OF QUARTERLY JOB APPLICATIONS EXACT SCIENCES Source: Exact Sciences internal data 19

  20. Slide 20: Creating a more sustainable, cancer-free world for future generations

    ATTRACT ATTRACT AND HIRE Creating a more sustainable, cancer-free world for future generations EXACT SCIENCES 20

  21. Slide 21: Developing and promoting career growth is key to our success

    DEVELOP & GROW DEVELOP Developing and promoting career growth is key to our success 330K 2 in 5 80%+ annual teammates enrolled of teammates participate training hours in mentorship program in wellness program EXACT SCIENCES Source: Exact Sciences internal data 21 21

  22. Slide 22: Fostering innovation through engagement

    RETAIN Fostering innovation through engagement GREAT PLACE TO WORK RESULTS 82% MAY 2023-MAY 2024 USA Best Workplaces in BiopharmaTM 57% Typical company Best-in-State Employer EXACT SCIENCES Source: Exact Sciences internal data 22

  23. Slide 23: Changing lives, together

    Changing lives, together EXACT SCIENCES 23

  24. Slide 24: Develop tests that impact decisions

    Develop tests that impact decisions Jorge Garces Chief Science Officer EXACT SCIENCES 24 24

  25. Slide 25: Invest in world-class talent dedicated to fighting cancer

    Invest in world-class talent dedicated to fighting cancer Drive profitable Offer tests that revenue impact decision-making Provide a seamless Generate experience for rock-solid clinical customers evidence Increase access & drive adoption EXACT SCIENCES 25

  26. Slide 26: Broad scientific capabilities & leadership

    Broad scientific capabilities & leadership OUR CAPACITY OUR TEAM 100K+ 285 square feet of operational scientists R&D lab space 4 110 PhDs in R&D R&D centers globally EXACT SCIENCES Source: Exact Sciences internal data 26

  27. Slide 27: Methodical approach to product and evidence development

    Methodical approach to product and evidence development Research & Adoption & Approval development access Sample & data Analytical Clinical performance Clinical Real-world collection performance & safety benefit vs. risk benefit vs. risk discovery, evaluation, sensitivity, specificity, sensitivity,

  28. Slide 28: Multi-omics is the answer

    Multi-omics is the answer Genomics Transcriptomics Proteomics (DNA) (RNA) (Proteins) Madison, WI San Diego, CA Madison, WI San Diego, CA Munich, Germany Boston, MA EXACT SCIENCES 28

  29. Slide 29: Methylation

    Methylation Unmatched marker discovery capabilities Sample acquisition Lung Breast Whole methylome Liver Ovary sequencing 500 Stomach Lymphoma methylation markers Marker selection validated across Colon Uterus Bile duct Cervix Marker refinement 16 of the Esophagus Melanoma deadliest cancers Marker t

  30. Slide 30: Markers with greatest signal to noise

    Methylation Unmatched marker discovery capabilities Discover markers in tissue Validate in blood, stool, other Marker selection process Dataset Healthy controls Ovarian cancers Learning Independent Markers with greatest signal to noise dataset test set Markers with Greatest Signal to Noise 5-fold cr

  31. Slide 31: Mutations

    Mutations Unmatched marker discovery capabilities EXACT SCIENCES 31

  32. Slide 32: Proteins

    Proteins Unmatched marker discovery capabilities Thousands 1 of proteins and phosphopeptides cancer sample Assay Platform Protein Discovery Platform Sample preparation Liquid chromatography Spectra interpretation Data analysis Mass spectrometry Protein quantification EXACT SCIENCES Source: Exact Sci

  33. Slide 33: Sequencing power for all applications with 60 platforms

    Sequencing power for all Expertise across technologies applications with 60 platforms with an automated platform 247K 26K 2.6K exomes transcriptomes genomes sequenced sequenced sequenced SANGER HIGH-THROUGHPUT NGS PRODUCTION-SCALE NGS SEQUENCING EXACT SCIENCES Source: Exact Sciences internal data 33

  34. Slide 34: SaferSeqS & RealSeqS

    SaferSeqS & RealSeqS Expertise across technologies with an automated platform Safer Sequencing System & Repetitive Element AneupLoidy Sequencing System Exact Sciences maintains exclusive rights Detects variants at frequencies below 1 in 100K DNA molecules Reduces the error rate of existing PCR-based

  35. Slide 35: TELQAS Chemistry

    TELQAS Chemistry TM Expertise across technologies with an automated platform Target Enrichment Long probe Quantitative Amplified Signal Developed and owned by Exact Sciences Single copy detection Faster time to result LQAS 120 LQAS 100 10K 100 Multiplex PCR 80 RFU 60 TaqMan 10K 40 Limited sample 12

  36. Slide 36: Exact Sciences is technology agnostic

    Exact Sciences is Expertise across technologies technology agnostic with an automated platform 300 130 60 Hamilton liquid handlers Real-time ABI 7500 systems Sequencers EXACT SCIENCES Source: Exact Sciences internal data 36

  37. Slide 37: LBgard

    LBgard ® Expertise across technologies with an automated platform Proprietary technology increases yield and decreases contamination 109% 52% increase in plasma recovery yield decrease in gDNA contamination Plastic external tube Glass internal coating Plasma Cell-free DNA (cfDNA) Proteins Exosomes B

  38. Slide 38: Proficiency optimizing comprehensive algorithms

    Proficiency optimizing comprehensive algorithms training cross validation independent sets validation sets test sets artificial neural networks 70 multi-marker approach proprietary chemistry person bioinformatics team machine learning classifier EXACT SCIENCES 38 38

  39. Slide 39: Strong intellectual property portfolio protects unique advantages

    Strong intellectual property portfolio protects unique advantages 900+ 400+ patents issued worldwide patent applications filed EXACT SCIENCES Source: Exact Sciences internal data 39

  40. Slide 40: Offer tests that impact decisions

    Offer tests that impact decisions Jake Orville General Manager, Screening EXACT SCIENCES 40

  41. Slide 41: How we help detect cancer earlier and provide smarter answers at every step

    How we help detect cancer earlier and provide smarter answers at every step Hereditary testing Screening & diagnosis MRD & recurrence expected 2023 multi-cancer liver, esophageal, & others Early-stage therapy Prognosis & prediction Includes tests in development, which are EXACT SCIENCES 41 not avail

  42. Slide 42: Providing the best screening tests to help prevent and detect cancer earlier

    Providing the best screening tests to help prevent and detect cancer earlier Hereditary Therapy selection testing & monitoring Screening & diagnosis MRD & recurrence expected 2023 multi-cancer liver, esophageal, & others Early-stage therapy Prognosis & prediction Includes tests in development, which

  43. Slide 43: Colorectal cancer: 60M unscreened Americans

    COLORECTAL CANCER Diagnosed in stage IV 60M unscreened Americans ages 45-85 1 out of 10 survive Source: Fisher D et al., ASCO Gastrointestinal Cancers Symposium (2022); Exact Sciences estimates based on 51% screening rate for ages 50-85 and 10-15% screening rate for ages 45-49; Siegel RL et al., Can

  44. Slide 44: Colorectal cancer: diagnosed in stages I & II

    COLORECTAL CANCER 94% 91% Diagnosed in stages I & II cancer sensitivity specificity 92% 87% Easy to use No sedation Non-invasive No time off work 9 out of 10 survive 24/7 support No preparation Source: Imperiale TF et al., N Engl J Med (2014); Siegel RL et al., Cancer Statistics (2022); Exact Scienc

  45. Slide 45: Colorectal cancer timeline

    COLORECTAL CANCER COLORECTAL CANCER FDA USPSTF approval guidelines Aug Jun Completed DeeP-C Medicare HEDIS 1M people 10M people Expected enrollment NCD measures screened screened USPSTF Nov Oct Oct Feb Nov update 2012 2014 2016 2018 2020 2022 2024 2026 2028 2013 2015 2017 2019 2021 2023 2025 2027 30

  46. Slide 46: 35M+ expected people screened by 2027

    COLORECTAL CANCER 35M+ expected people screened by 2027 expected people screened by 2027 EXACT SCIENCES 46

  47. Slide 47: A test and services

    COLORECTAL CANCER A test and Options services and services EXACT SCIENCES 47

  48. Slide 48: Multi-cancer: diagnosed in stage IV

    MULTI-CANCER Diagnosed in stage IV 70% of cancers have no SCREENING OPTIONS 2 out of 10 survive Source: United States Preventive Services Task Force. A and B recommendations (2022); Siegel RL et al., A. Cancer Statistics (2021); Siegel DA et al., JAMA Oncol. (2021); Richards TB et al. Morb Mortal Wk

  49. Slide 49: Multi-cancer: 135M Americans ages 45-85

    MULTI-CANCER Diagnosed in stage I 135M Americans ages 45-85 8 out of 10 survive Source: U.S. Census data; American Cancer Society statistics on average 5-year relative survival rates for 19 leading cancers EXACT SCIENCES 49

  50. Slide 50: DETECT-A

    MULTI-CANCER Adding mutation to methylation improves accuracy The first prospective study 35% improvement in early-stage sensitivity 10K asymptomatic people DETECT-A 29% 39% Doubled cancers found compared to SOC alone 2/3 were earlier stages 3 marker 4 marker classes classes Case-control data presen

  51. Slide 51: Refine clinical implementation practices

    MULTI-CANCER Refine clinical implementation practices Generate real-world evidence Optimize ordering workflow EXACT SCIENCES 51

  52. Slide 52: Exact Sciences acquires Thrive

    BUILT ON THE EXACT SCIENCES TO CREATE FOUNDATION CREATED BY ACQUIRES THRIVE TM EXACT SCIENCES 52

  53. Slide 53: How we help detect cancer earlier and provide smarter answers at every step

    How we help detect cancer earlier and provide smarter answers at every step Hereditary testing Screening & diagnosis MRD & recurrence expected 2023 liver, esophageal, & others Early-stage therapy Prognosis & prediction Includes tests in development, which are EXACT SCIENCES 53 not available for sale

  54. Slide 54: Offer tests that impact decisions

    Offer tests that impact decisions Brian Baranick General Manager, Precision Oncology EXACT SCIENCES 54

  55. Slide 55: Enabling personalized medicine through our Precision Oncology portfolio

    Enabling personalized medicine through our Precision Oncology portfolio Hereditary testing Screening & diagnosis MRD & recurrence expected 2023 liver, esophageal, & others Early-stage therapy Prognosis & prediction Includes tests in development, which are EXACT SCIENCES 55 not available for sale or

  56. Slide 56: Katie Couric video

    KATIE COURIC VIDEO https://exactsciences.app.box.com/s/z od7dxyokb5iyeanxe4t2rrn841nnkoi 56 EXACT SCIENCES 56

  57. Slide 57: Oncotype DX established a new standard in personalized cancer care

    Oncotype DX established a new standard in personalized cancer care ~1.2M ~1M $400M+ 80%+ cumulative U.S. U.S. patients spared U.S. U.S. market patients tested unnecessary chemotherapy revenue penetration EXACT SCIENCES Source: Sparano et al., N Engl J Med (2018); Geyer et al., NPJ Breast Cancer (201

  58. Slide 58: Oncotype DX is supported by unmatched evidence and all major guidelines

    Oncotype DX is supported by unmatched evidence and all major guidelines 100K+ patients with published prospective outcomes TAILORx RxPONDER 10K women, 12 years 5K women, 5 years ASCO® NCCN® ESMO ST. GALLEN NICE Range: 0-100 EXACT SCIENCES Source: Sparano et al., N Engl J Med (2018); Geyer et al., NP

  59. Slide 59: Oncotype DX provides an international Precision Oncology footprint

    Oncotype DX provides an international Precision Oncology footprint 110 120 sales team country members presence Solidify standard of care in established markets + Increase adoption in growing markets Launch in new markets EXACT SCIENCES Source: Exact Sciences internal data 59

  60. Slide 60: Our platform provides unique advantages in Precision Oncology

    Our platform provides unique advantages in Precision Oncology Commercial channel EMR platform Relationships with 90%+ of oncologists Seamless ordering and resulting Tissue access Patient compliance engine ~200K samples each year Facilitates recurring testing Global footprint Lab operations excellenc

  61. Slide 61: Hybrid capture technology

    Hybrid capture technology Targets and captures specific DNA fragments Proprietary detection algorithm Operationally reliable Superior LBgard® collection tubes EXACT SCIENCES 61

  62. Slide 62: Whole genome technology

    Whole genome technology Expanded breadth of mutations Attractive cost profile EXACT SCIENCES 62

  63. Slide 63: Universal platform supports entrance into colon cancer and expansion soon after

    Universal platform supports entrance into colon cancer and expansion soon after COLON BREAST ADDITIONAL CANCER CANCER CANCER TYPES Second largest opportunity Largest opportunity Universal MRD platform Established evidence & Demonstrate clinical utility Tumor-informed and reimbursement through partne

  64. Slide 64: Providing ultra-comprehensive genomic profiling, including DNA and RNA

    Providing ultra-comprehensive genomic profiling, including DNA and RNA 20,000 genes DNA (tumor + inherited) ~325 20,000+ targets RNA ~50 Protein Other tests OncoExTra EXACT SCIENCES Source: Exact Sciences internal data 64

  65. Slide 65: Selena: hereditary cancer

    HEREDITARY CANCER + - + - 48 MRD BASELINE RS result + - MRD SURVEILLANCE + - Selena, MRD SURVEILLANCE + - a colorectal cancer patient MRD SURVEILLANCE + - 65 EXACT SCIENCES Illustrative example, not a real patient

  66. Slide 66: Selena: screening

    SCREENING + - + - 48 MRD BASELINE RS result + - + - MRD SURVEILLANCE Selena, MRD SURVEILLANCE + - a colorectal cancer patient MRD SURVEILLANCE + - 66 EXACT SCIENCES Illustrative example, not a real patient

  67. Slide 67: Selena: early-stage cancer

    EARLY-STAGE CANCER + - + - 48 MRD BASELINE RS result + - MRD SURVEILLANCE + - Selena, MRD SURVEILLANCE + - a colorectal cancer patient MRD SURVEILLANCE + - 67 EXACT SCIENCES Illustrative example, not a real patient

  68. Slide 68: Selena: recurrence testing

    RECURRENCE TESTING + - + - 48 MRD BASELINE RS result + - MRD SURVEILLANCE + - Selena, MRD SURVEILLANCE + - a colorectal cancer patient MRD SURVEILLANCE + - 68 EXACT SCIENCES Illustrative example, not a real patient

  69. Slide 69: Selena: relapse

    RELAPSE + - + - 48 MRD BASELINE RS result + - MRD SURVEILLANCE + - Selena, MRD SURVEILLANCE + - a colorectal cancer patient MRD SURVEILLANCE + - 69 EXACT SCIENCES Illustrative example, not a real patient

  70. Slide 70: Generate rock-solid evidence

    Generate rock- solid evidence Jorge Garces Chief Science Officer EXACT SCIENCES 70 70

  71. Slide 71: Invest in world-class talent dedicated to fighting cancer

    Invest in world-class talent dedicated to fighting cancer Drive profitable Offer tests that revenue impact decision-making Provide a seamless Generate experience for rock-solid clinical customers evidence Increase access & drive adoption EXACT SCIENCES 71

  72. Slide 72: Generating evidence "the Exact way"

    Generating evidence “the Exact way” Clinical Real-world Modeling trials definitively evidence and studies establishing test long-term outcomes demonstrating performance supporting test use population impact EXACT SCIENCES 72 72

  73. Slide 73: Exact Sciences conducts studies that make a difference over the long term

    Exact Sciences conducts studies that make a difference over the long term TAILOR-X 10K 6 RxPONDER 5K DeeP-C 10K NEJM publications DETECT-A 10K BLUE-C 20K Source: Sparano JA et al., N Engl J Med (2018); Kalinsky K et al., N Engl J Med (2021); Imperiale TF et al., N Engl J Med (2014); Paik S et al., N

  74. Slide 74: We have access to more than 1.1M high-quality samples

    We have access to more than 1.1M high-quality samples Aliquots in storage by sample type 439K 100+ Clinical Affairs team members 271K 275+ completed/ongoing clinical studies 186K 292K+ 116K 69K cumulative people enrolled 10K 9K 1K Plasma Stool Buffy coat Serum Tissue Cell pellet Blood Urine EXACT SC

  75. Slide 75: BLUE-C

    CLINICAL TRIALS BLUE-C 94% cancer Category, n (%) BLUE-C (n=20,208) DeeP-C (n=9,989) sensitivity Colorectal cancer 98 (0.48) 65 (0.65) next-generation Advanced pre- 2,146 (10.6) 757 (7.6) cancerous lesions Non-advanced 6,983 (34.6) 2,893 (29.0) 91% adenomas specificity including non- Negative 10,981

  76. Slide 76: DETECT-A real-world evidence

    REAL-WORLD EVIDENCE DETECT-A 100% 86% <1% of early-stage diagnosed and of surgically-treated of false-positive results treated patients still living patients in remission developed cancer annually cancer free over 4 years EXACT SCIENCES Source: Buchannan A et al., ASCO (2023); Lennon A et al., ASCO

  77. Slide 77: SEER data

    REAL-WORLD EVIDENCE SEER data 90K patients with invasive breast cancer Confirmed Oncotype DX was prognostic for 9 years breast cancer-specific mortality of follow up EXACT SCIENCES 77 Source: Geyer C et al., ASCO abstract (2023)

  78. Slide 78: Modeling studies

    MODELING STUDIES 100+ 40K+ 21K health economic studies scenarios lines of code in one in the last 3 years simulated colorectal cancer model EXACT SCIENCES Source: Exact Sciences internal data 78

  79. Slide 79: Cologuard and Cancerguard

    es, cologuard® EXACT SCIENCES aw cancerguard 79

  80. Slide 80: Increase access and drive adoption

    Increase access and drive adoption Everett Cunningham Chief Commercial Officer EXACT SCIENCES 80 80

  81. Slide 81: Invest in world-class talent dedicated to fighting cancer

    Invest in world-class talent dedicated to fighting cancer Drive profitable Offer tests that revenue impact decision-making Provide a seamless Generate experience for rock-solid clinical customers evidence Increase access & drive adoption EXACT SCIENCES 81

  82. Slide 82: 1,200 person commercial organization

    1,200 1,000 person commercial person field team organization Primary care Oncology Field Health Provider Medical Women’s team technology marketing geneticists health Surgeons Health Consumer Market Gastro- systems marketing access enterology International oncology Source: Exact Sciences internal dat

  83. Slide 83: The most powerful commercial engine in diagnostics

    The most powerful commercial engine in diagnostics PATIENTS HEALTH CARE HEALTH PAYERS PHARMA PROFESSIONALS SYSTEMS 85% 370K 275 780 60 brand cumulative providers electronic in-network biopharma awareness have ordered connections agreements partnerships EXACT SCIENCES Source: Exact Sciences internal

  84. Slide 84: Deploying an all-encompassing sales and marketing strategy

    Deploying an all-encompassing sales and marketing strategy Educating Health systems Surround health care and payer sound professionals relationships marketing EXACT SCIENCES 84 84

  85. Slide 85: 1.6M+ field calls each year

    EDUCATING HEALTH CARE PROFESSIONALS 1.6M+ FIELD CALLS EACH YEAR EXACT SCIENCES Source: Exact Sciences internal data 85 85

  86. Slide 86: Data-driven insights promote agility and consistency

    EDUCATING HEALTH CARE Educating PROFESSIONALS Data-driven insights promote health care agility and consistency professionals EXACT SCIENCES 86

  87. Slide 87: Educating health care professionals

    EDUCATING HEALTH CARE PROFESSIONALS EXACT SCIENCES 87

  88. Slide 88: Health technology solutions

    HEALTH SYSTEM & PAYER RELATIONSHIPS 85 strategic account managers Targets 400 largest U.S. health systems Health technology 60 solutions oncology centers and integrated delivery networks EXACT SCIENCES 88 88 Source: Exact Sciences internal data

  89. Slide 89: Cologuard ordering through health systems

    HEALTH SYSTEM & PAYER RELATIONSHIPS INFORMATION TECHNOLOGY SUPPORT 90% Cologuard of 21K unscreened people auto ordered for cancelled or being ordered a Cologuard no-show colonoscopies EXACT SCIENCES Source: Exact Sciences internal data 89

  90. Slide 90: Sizzle reel video

    SURROUND SOUND MARKETING Sizzle reel video EXACT SCIENCES 90 90

  91. Slide 91: 10B+ advertisement impressions each year

    SURROUND SOUND MARKETING TRADITIONAL VIDEO SOCIAL 10B+ advertisement impressions each year VIDEO STREAMING SEARCH RADIO HCP CHANNELS Source: Exact Sciences internal data EXACT SCIENCES 91

  92. Slide 92: Optimizing spend as revenue grows

    Optimizing spend as revenue grows Total revenue Sales & marketing expense $2.40B $2.08B $1.77B $1.49B $876M 63% 50% 49% 41% 35% Low $454M 40% 30’s 52% $266M 44% 44% $99M 55% 55% 114% 112% 58% 58% 2016 2017 2018 2019 2020 2021 2022 2023E EXACT SCIENCES 2023E is midpoint of Exact Sciences guidance pro

  93. Slide 93: Provide seamless experience

    Provide seamless experience Everett Cunningham Chief Commercial Officer EXACT SCIENCES 93

  94. Slide 94: Invest in world-class talent dedicated to fighting cancer

    Invest in world-class talent dedicated to fighting cancer Drive profitable Offer tests that revenue impact decision-making Provide a seamless Generate experience for rock-solid clinical customers evidence Increase access & drive adoption EXACT SCIENCES 94

  95. Slide 95: We don't just have great tests, we offer great services

    We don’t just have great tests, we offer great services EXACT SCIENCES 95

  96. Slide 96: 15M+ patient calls each year

    15M+ 75%+ patient calls enabled each year by technology EXACT SCIENCES 96 Source: Exact Sciences internal data

  97. Slide 97: Investing in a seamless customer experience

    Investing in a seamless customer experience Customer experience Customer support team Test volume $131M $113M $87M $62M Source: Exact Sciences internal data EXACT SCIENCES 97 2020 2021 2022 2023E

  98. Slide 98: We have been working to perfect the customer experience for nearly a decade

    We have been working to perfect the customer experience for nearly a decade 220+ experiments conducted EXACT SCIENCES Source: Exact Sciences internal data 98

  99. Slide 99: Cologuard kit return app improving ease of use

    Cologuard kit return “app” improving ease of use doubled completion rate of schedule UPS pickup feature 3 min  30 seconds amount of time to complete task 8 min 5.5 min total app time Source: Exact Sciences internal data EXACT SCIENCES 99

  100. Slide 100: Challenges in cancer care

    Challenges in cancer care Waiting for answers until follow-up visit; anxious about having cancer Unaware/unsure of Overwhelmed by Overwhelmed by tumor profiling Difficult to keep track of screening tests Anxious for results; test diagnosis – don’t know info – don’t know where to get when next test/

  101. Slide 101: Challenges in cancer care

    Challenges in cancer care Telehealth tool provides convenient access to provider for questions Track sample throughout process; know when result is ready Receive reminders and Digital tool shows Waiting for answers until Diagnosis details links to re-order tests, provider and patient they follow-up

  102. Slide 102: Drive profitable revenue

    Drive profitable revenue Jeff Elliott Chief Financial Officer EXACTSCIENCES EXACT SCIENCES 102

  103. Slide 103: Invest in world-class talent dedicated to fighting cancer

    Invest in world-class talent dedicated to fighting cancer Drive profitable Offer tests that revenue impact decision-making Provide a seamless Generate experience for rock-solid clinical customers evidence Increase access & drive adoption EXACT SCIENCES 103

  104. Slide 104: Grow the core business, increase profits, allocate capital

    Grow the Increase profits Allocate core business and cash flow capital EXACTSCIENCES EXACT SCIENCES 104

  105. Slide 105: Q1 was a record-breaking quarter

    GROW THE CORE BUSINESS Q1 was a record-breaking quarter Core revenue Non-GAAP gross margin Adjusted EBITDA Free cash flow +33% +1.7 pts +$136M +$140M $598M 74.0% $450M 72.3% $46M ($68M) ($90M) ($207M) 1Q22 1Q23 1Q22 1Q23 1Q22 1Q23 1Q22 1Q23 Please refer to the appendix accompanying this presentation

  106. Slide 106: Financial targets

    GROW THE CORE BUSINESS FINANCIAL TARGETS ~15% 20%+ compounded annual adjusted EBITDA revenue growth 2022-2027 margin in 2027 (excluding COVID and prostate) Note: compounded annual revenue growth based on total revenue in 2022, excluding revenue generated from COVID-19 testing and the divested Oncoty

  107. Slide 107: Screening revenue

    GROW THE CORE BUSINESS Screening revenue 8-year CAGR: 60%+ $1.78B Growth drivers $1.42B Rescreens $1.06B 45-49 age group $810M $815M Commercial productivity $454M $266M Health system connections $99M $39M 2015 2016 2017 2018 2019 2020 2021 2022 2023E CAGR revenue calculated using GAAP figures; 2023E

  108. Slide 108: Precision Oncology revenue

    GROW THE CORE BUSINESS Precision Oncology revenue 5-year CAGR: 9% $613M Growth drivers $601M $562M International expansion $456M $440M $394M Node-positive adoption Therapy selection Biopharma partnerships 2018 2019 2020 2021 2022 2023E CAGR revenue calculated using GAAP figures; 2023E is midpoint of

  109. Slide 109: Non-GAAP gross profit

    GROW THE CORE BUSINESS Non-GAAP gross profit 8-year CAGR: 80%+ $1.75B 73%+ $1.51B Key drivers Non-GAAP gross margin $1.31B Volume leverage $1.14B Automation projects $660M Rescreen mix increasing $338M $188M Next-generation Cologuard $15M $54M 2015 2016 2017 2018 2019 2020 2021 2022 2023E 2023E is m

  110. Slide 110: Adjusted EBITDA grew $136M Y/Y

    INCREASE PROFITS & CASH FLOW Adjusted EBITDA Expect adjusted EBITDA margin grew $136M Y/Y to increase 15 pts by 2027 $46M 2023 guidance 2027 target $5M ($13M) 5% 20%+ ($46M) ($90M) 1Q22 2Q22 3Q22 4Q22 1Q23 2023 guidance for adjusted EBITDA margin refers to midpoint of guidance provided on May 9, 202

  111. Slide 111: Rescreen eligibility and compliance

    INCREASE PROFITS & CASH FLOW Eligible for second rescreen Eligible for first rescreen ~30 pt 0.4M 0.3M higher compliance for 2nd rescreen 0.1M ~20 pt 2.0M 1.7M 1.3M 1.3M 0.8M higher compliance for 1st rescreen 2021 2022 2023E 2024E 2025E Source: Exact Sciences internal data based on 90-day adherence

  112. Slide 112: Free cash flow

    INCREASE PROFITS & CASH FLOW Free cash flow Positive ($21M) ($68M) ($86M) ($124M) 2Q22 3Q22 4Q22 1Q23 2Q23E Please refer to the appendix accompanying this presentation for discussion of non-GAAP financial measures and reconciliations to GAAP financial measures EXACTSCIENCES EXACT SCIENCES 112

  113. Slide 113: Disciplined capital allocation

    ALLOCATE CAPITAL Core Pipeline Retaining business opportunities cash flow Disciplined capital allocation EXACTSCIENCES EXACT SCIENCES 113

  114. Slide 114: 20-day decrease in DSOs

    ALLOCATE CAPITAL 50 20-day 35K 99% decrease in decrease in DSOs Cologuard claim errors 30K 45 25K 40 20K 35 15K 30 10K 25 5K 20 0K Jan 22 Mar 22 May 22 Jul 22 Sep 22 Nov 22 Jan 23 Mar 23 Jan 22 Mar 22 May 22 Jul 22 Sep 22 Nov 22 Jan 23 Mar 23 Source: Exact Sciences internal data EXACTSCIENCES EXACT

  115. Slide 115: Enhancing our state-of-the-art labs

    ALLOCATE CAPITAL Enhancing our state-of-the-art labs $200M cumulative cost savings expected by 2030 EXACTSCIENCES EXACT SCIENCES 115

  116. Slide 116: Market size and penetration

    ALLOCATE CAPITAL Market size ($) MCED $25B CRC MRD $18B $15B Therapy selection Liver Hereditary cancer testing Pancreatic Lung Breast Rare disease Thyroid Esophageal 0% 20% 40% 60% 80% 100% Total market penetration Source: U.S. Census data and Exact Sciences estimates; U.S. markets only EXACT SCIENC

  117. Slide 117: Incremental revenue growth and non-GAAP gross profit vs Dx group

    ~7x incremental ~8x non-GAAP gross revenue growth profit dollars $316M $1.75B $44M $230M 1 2 1 2 Dx group Dx group average average Source: Exact Sciences guidance provided May 9, 2023; FactSet Dx group includes 23andMe, Adaptive, GeneDX, Guardant Health, Invitae, Myriad, Natera, NeoGenomics, Persona

  118. Slide 118: Expert health care professional panel

    Expert health care professional panel Seth A. Gross Lisa Ravindra Ronan J. Kelly Charles Geyer MD, FACG, FASGE, AGAF MD, FACP MD, MBA MD, FACP Professor of Medicine Assistant Professor of Medicine, Director of the Charles A. Sammons Cancer Center, Chief Scientific Officer, Clinical Chief, Division o

  119. Slide 119: EXACT SCIENCES

    EXACTSCIENCES EXACT SCIENCES 119 119

  120. Slide 120: Exact Sciences is a powerful innovator and growth engine

    Exact Sciences is a powerful innovator and growth engine our team powers best-in-class profitable growth our flywheel scientific capabilities for years to come EXACT SCIENCES 120

  121. Slide 121: We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment

    We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment. EXACT SCIENCES SCIENCES 121 EXACT

  122. Slide 122: Appendix: Non-GAAP disclosure

    Appendix Non-GAAP disclosure In addition to the company's financial results determined in accordance with U.S. GAAP, the company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. The company presents EBITDA, adjusted EBITDA, non-GAAP gr

  123. Slide 123: EBITDA and Adjusted EBITDA Reconciliations

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information EBITDA and Adjusted EBITDA Reconciliations (Amounts in thousands) (In thousands) 1Q22 2Q22 3Q22 4Q22 1Q23 Net loss $ (180,937) $ (166,063) $ (148,761) $ (127,745) $ (74,151) Interest expense (income) (1) 4,478 4,511 5,235 5,410 (4,1

  124. Slide 124: Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations (Amounts in thousands) 1Q23 1Q22 Revenue $ 602,450 $ 486,571 Cost of sales (exclusive of amortization of acquired intangible assets) 156,866 134,705 Amortization of acq

  125. Slide 125: Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations (Amounts in thousands) For the Year Ended 2015 2016 2017 2018 2019 2020 2021 2022 Revenue $ 39,437 $ 99,376 $ 265,989 $ 454,462 $ 876,293 $ 1,491,391 $ 1,767,087 $ 2,08

  126. Slide 126: Reconciliation of Core Revenue

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of Core Revenue (Amounts in thousands) GAAP 1Q23 1Q22 % Change Screening $ 443,195 $ 306,522 45 % Precision Oncology 155,432 152,620 2 % COVID-19 Testing 3,823 27,429 (86) % Total $ 602,450 $ 486,571 24 % Non-GAAP For

  127. Slide 127: Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow (Amounts in thousands) 1Q22 2Q22 3Q22 4Q22 1Q23 Net cash provided by (used in) operating activities $ (173,754) $ (60,916) $ (40,926) $ 52,037 $ (3

Exact Sciences — Investor Day (June 2023) on 6ix